Question-and-Answer Session
Operator
(Operator Instructions) Our first question comes from the line Joel Sendek with Lazard Capital. Please proceed with your question.
Joel Sendek - Lazard Capital Markets
Thanks. So, I just have a clarification question on Cinryze. So, I think you said you had some people on drug at year end but its 90 days from enrollment to receive reimbursement and receive the drug I'm just confused what I'm missing there?
Dan Soland
So, Joel, this is Dan, very good question and what we are suggesting is that on average for the average patient it's about 90 days. You know obviously, there are some patients who are unable to get our drug in literally less than 30 days. And there will be others who will probably go up to 120 days. But on average, we think for this initial group of patients it will be about 90 days to reimbursement.
Joel Sendek - Lazard Capital Markets
Okay so you have people right now who are on drug and being reimbursed currently?
Dan Soland
That's correct.
Joel Sendek - Lazard Capital Markets
And how many people can you tell us again were on the open label studies and are therefore being rolled over into the solutions program?
Dan Soland
In the prophylaxis studies Joel, I think there are approximately 150 patients between Cetor and Cinryze.
Joel Sendek - Lazard Capital Markets
And then the reason you are not giving guidance is just too complicated with, or do you have too many unknowns with regard to figuring out the price and all that, all those moving parts not because you do not think the revenues are going to be material this year.
Vince Milano
Yeah I think Joel, the way we are going to answer that question is not their unknown is one way to put it to variables right. And so the context of the variables are not only the number of patients but certainly the number of doses per patient. As we have spoken about in the past the open label study had an average of about 1.7 and 1.8 doses per patient and we anticipate that there will be variability both up from there and may be down from there as well.
And so our focus is on number of doses per patient and we do not have much information yet certainly at the moment to comment. And then also the payer mix as you pointed out and the time frame for reimbursement. So there is a number of variables here in the early days, that give us pause in terms of providing guidance. So that we can have appropriate expectation set.
- To read the full transcript on Seeking Alpha, click here »
